Cargando…

Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3

OBJECTIVE: MicroRNA-143 (miR-145) has shown promising tumor-suppressive effects in different types of cancer and could potentially act as a tumor suppressor in liver cancer. To explore this further, the present study aims to investigate the protective function of miR-145 in human liver cancer. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yongqiang, Liu, Junhao, Hu, Xiao, Zeng, Xiancheng, Gao, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royan Institute 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542210/
https://www.ncbi.nlm.nih.gov/pubmed/37641416
http://dx.doi.org/10.22074/CELLJ.2023.1995666.1251
_version_ 1785114044756131840
author Lai, Yongqiang
Liu, Junhao
Hu, Xiao
Zeng, Xiancheng
Gao, Peng
author_facet Lai, Yongqiang
Liu, Junhao
Hu, Xiao
Zeng, Xiancheng
Gao, Peng
author_sort Lai, Yongqiang
collection PubMed
description OBJECTIVE: MicroRNA-143 (miR-145) has shown promising tumor-suppressive effects in different types of cancer and could potentially act as a tumor suppressor in liver cancer. To explore this further, the present study aims to investigate the protective function of miR-145 in human liver cancer. MATERIALS AND METHODS: In this experimental study, we analyzed miR-145 expression in human tissue samples and liver cancer cell lines using quantitative real time polymerase chain reaction (qRT-PCR). Cancer cell lines were transfected using Lipofectamine 2000. We assessed cell viability of HepG2 liver cancer cell line using the MTT assay and analyzed colony forming potential through clonogenic assay. Flow cytometry was employed to evaluate cell cycle phase distribution in cancer cell lines expressing either miR-145 inhibitor or miR-145 mimics. The motility of cancer cell lines was determined using the transwell chamber assay. Protein expression levels of Cyclin B1 and CDCA3, important for cell cycle progression and cell division, respectively, were measured using western blotting. Finally, we conducted a dual luciferase assay to investigate the interaction between miR-145 and CDCA3. RESULTS: Downregulation of miR-145 was observed in liver cancer cells. Overexpression of miR-145 through transfection inhibited cancer cell proliferation, while transfection of miR-145 inhibitor increased proliferation rate. MiR- 145 overexpression led to cell cycle arrest at the G2/M phase by suppressing cyclin B1 protein expression. Moreover, miR-145 overexpression suppressed migration and invasion of cancer cells. CDCA3 gene was identified as the intracellular target of miR-145, and the inhibitory effects of miR-145 were mediated through the CDCA3 protein. CONCLUSION: MiR-145 regulates CDCA3 in liver cancer, affecting its development. Decreased miR-145 allows CDCA3 accumulation, promoting liver cancer progression. MiR-145 targets CDCA3 to inhibit viability, migration, and invasion of liver cancer cells. Further research is needed to understand miR-145's regulatory role and develop more effective strategies against liver cancer.
format Online
Article
Text
id pubmed-10542210
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Royan Institute
record_format MEDLINE/PubMed
spelling pubmed-105422102023-10-03 Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3 Lai, Yongqiang Liu, Junhao Hu, Xiao Zeng, Xiancheng Gao, Peng Cell J Original Article OBJECTIVE: MicroRNA-143 (miR-145) has shown promising tumor-suppressive effects in different types of cancer and could potentially act as a tumor suppressor in liver cancer. To explore this further, the present study aims to investigate the protective function of miR-145 in human liver cancer. MATERIALS AND METHODS: In this experimental study, we analyzed miR-145 expression in human tissue samples and liver cancer cell lines using quantitative real time polymerase chain reaction (qRT-PCR). Cancer cell lines were transfected using Lipofectamine 2000. We assessed cell viability of HepG2 liver cancer cell line using the MTT assay and analyzed colony forming potential through clonogenic assay. Flow cytometry was employed to evaluate cell cycle phase distribution in cancer cell lines expressing either miR-145 inhibitor or miR-145 mimics. The motility of cancer cell lines was determined using the transwell chamber assay. Protein expression levels of Cyclin B1 and CDCA3, important for cell cycle progression and cell division, respectively, were measured using western blotting. Finally, we conducted a dual luciferase assay to investigate the interaction between miR-145 and CDCA3. RESULTS: Downregulation of miR-145 was observed in liver cancer cells. Overexpression of miR-145 through transfection inhibited cancer cell proliferation, while transfection of miR-145 inhibitor increased proliferation rate. MiR- 145 overexpression led to cell cycle arrest at the G2/M phase by suppressing cyclin B1 protein expression. Moreover, miR-145 overexpression suppressed migration and invasion of cancer cells. CDCA3 gene was identified as the intracellular target of miR-145, and the inhibitory effects of miR-145 were mediated through the CDCA3 protein. CONCLUSION: MiR-145 regulates CDCA3 in liver cancer, affecting its development. Decreased miR-145 allows CDCA3 accumulation, promoting liver cancer progression. MiR-145 targets CDCA3 to inhibit viability, migration, and invasion of liver cancer cells. Further research is needed to understand miR-145's regulatory role and develop more effective strategies against liver cancer. Royan Institute 2023-08 2023-08-20 /pmc/articles/PMC10542210/ /pubmed/37641416 http://dx.doi.org/10.22074/CELLJ.2023.1995666.1251 Text en Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. https://creativecommons.org/licenses/by-nc/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lai, Yongqiang
Liu, Junhao
Hu, Xiao
Zeng, Xiancheng
Gao, Peng
Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title_full Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title_fullStr Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title_full_unstemmed Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title_short Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3
title_sort modifications of the human liver cancer cells through microrna-145-mediated targeting of cdca3
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542210/
https://www.ncbi.nlm.nih.gov/pubmed/37641416
http://dx.doi.org/10.22074/CELLJ.2023.1995666.1251
work_keys_str_mv AT laiyongqiang modificationsofthehumanlivercancercellsthroughmicrorna145mediatedtargetingofcdca3
AT liujunhao modificationsofthehumanlivercancercellsthroughmicrorna145mediatedtargetingofcdca3
AT huxiao modificationsofthehumanlivercancercellsthroughmicrorna145mediatedtargetingofcdca3
AT zengxiancheng modificationsofthehumanlivercancercellsthroughmicrorna145mediatedtargetingofcdca3
AT gaopeng modificationsofthehumanlivercancercellsthroughmicrorna145mediatedtargetingofcdca3